Vladislav Semak

Dr. Vladislav Semak

Danube University Krems
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 May 2011 in European Journal of Organic Chemistry
Verified
Journal Article
Closed access
PDF file
CACarlos Arróniz
Carlos Arróniz
AGAlberto Gil‐González
Alberto Gil‐González
VSVladislav Semak
Vladislav Semak
CECarmen Escolano
Carmen Escolano
JBJoan Bosch
Joan Bosch
MAMercedes Amat
Mercedes Amat

1 July 2013 in Analytical Chemistry
Verified
Journal Article
Closed access
TBTomáš Bertók
Tomáš Bertók
LKLudmila Klukova
Ludmila Klukova
ASAlena Sediva
Alena Sediva
Peter KasakPeter Kasak
Peter Kasak
VSVladislav Semak
Vladislav Semak
Jan TkacJan Tkac
Jan Tkac

4 December 2014 in Organic Letters
Verified
Journal Article
Closed access
Peter HrobarikPeter Hrobarik
Peter Hrobarik
VHVeronika Hrobáriková
Veronika Hrobáriková
VSVladislav Semak
Vladislav Semak
Peter KasakPeter Kasak
Peter Kasak
ERErik Rakovský
Erik Rakovský
PPPeter Persephonis
Peter Persephonis

1 April 2013 in Current Alzheimer Research
Verified
Journal Article
Closed access
PDF file
EAEster Aso
Ester Aso
JSJana Semakova
Jana Semakova
LJLaura Joda
Laura Joda
VSVladislav Semak
Vladislav Semak
LHLyda Halbaut-Bellowa
Lyda Halbaut-Bellowa
IFIsidro Ferrer
Isidro Ferrer
Diets containing a high proportion of fat with respect to protein plus carbohydrates are capable of inducing ketone body production in the liver, which provides an energetic alternative to glucose. Some ketogenic diets have been tested as therapeutic strategies for treating metabolic disorders related to a deficiency in glucose-driven ATP generation. However, ketone bodies are not capable of providing extra tricarboxylic acid cycle intermediates, limiting the anabolic capacity of the cell. Therefore, it is reasonable to hypothesize that supplementing a ketogenic diet with anaplerotic compounds such as triheptanoin may improve ketogenic diet effectiveness. The present study tests this hypothesis in APP/PS1 (APPswe/PS1dE9) transgenic mice, used as a model of familial Alzheimer’s disease because impaired energy supply to neurons has been linked to this neurodegenerative process. Triheptanoin supplementation to a ketogenic diet for three months and starting at the age of three months reduces the memory impairment of APP/PS1 mice at the age of 6 months. The Aβ production and deposition were not significantly altered by the ketogenic diet, supplemented or not by triheptanoin. However, mice fed with triheptanoin-rich ketogenic diet have shown decreased astroglial response in the vicinity of Aβ plaques and decreased expression of the pro-inflammatory cytokine interferon-γ in astrocytes. These findings correlate with transcriptional up-regulation of the ROS detoxifying mechanisms Sirt1 and Pparg, thus linking triheptanoin with improved mitochondrial status. Present findings support the concept that ketogenic diets supplemented with anaplerotic compounds can be considered potential therapeutic strategies at early stages of Alzheimer’s disease.

27 October 2014 in Macromolecular Chemistry and Physics
Verified
Journal Article
Closed access
PDF file
ILIgor Lacík
Igor Lacík
MSMarek Stach
Marek Stach
Peter KasakPeter Kasak
Peter Kasak
VSVladislav Semak
Vladislav Semak
LULucia Uhelská
Lucia Uhelská
MBMichael Buback
Michael Buback

Verified
Journal Article
Open access
PDF file
SGSobha Karuthedom George
Sobha Karuthedom George
LLLucia Lauková
Lucia Lauková
RWRené Weiss
René Weiss
VSVladislav Semak
Vladislav Semak
BFBirgit Fendl
Birgit Fendl
VWViktoria Weber
Viktoria Weber
Growing interest in extracellular vesicles (EVs) has prompted the advancements of protocols for improved EV characterization. As a high-throughput, multi-parameter, and single particle technique, flow cytometry is widely used for EV characterization. The comparison of data on EV concentration, however, is hindered by the lack of standardization between different protocols and instruments. Here, we quantified EV counts of platelet-derived EVs, using two flow cytometers (Gallios and CytoFLEX LX) and nanoparticle tracking analysis (NTA). Phosphatidylserine-exposing EVs were identified by labelling with lactadherin (LA). Calibration with silica-based fluorescent beads showed detection limits of 300 nm and 150 nm for Gallios and CytoFLEX LX, respectively. Accordingly, CytoFLEX LX yielded 40-fold higher EV counts and 13-fold higher counts of LA+CD41+ EVs compared to Gallios. NTA in fluorescence mode (F-NTA) demonstrated that only 9.5% of all vesicles detected in scatter mode exposed phosphatidylserine, resulting in good agreement of LA+ EVs for CytoFLEX LX and F-NTA. Since certain functional characteristics, such as the exposure of pro-coagulant phosphatidylserine, are not equally displayed across the entire EV size range, our study highlights the necessity of indicating the size range of EVs detected with a given approach along with the EV concentration to support the comparability between different studies.